Scandinavian Journal of Gastroenterology · 2015 · 40 citations · 24 references
MedicinePharmacotherapyAutoimmunityImmunopathologyInflammationAutoimmune DiseasesCorticosteroid TherapyPancreatic DiseasesPancreatic DisordersComparative Efficacy Of CorticosteroidsCorticosteroid RegimensCorticosteroid Side Effect ManagementLong-term Corticosteroid ManagementLong-term Outcome PredictionPrednisone UseStandardized Incidence RatioSteroid Therapy Management
OBJECTIVES: Autoimmune pancreatitis (AIP) responds well to corticosteroid therapy (CST), and CST is essential to induce remission. However, the correlation between long-term outcome and CST has not been evaluated. We aimed to clarify the correlation between long-term outcome of AIP and CST. MATERIAL AND METHODS: We retrospectively evaluated relapse, risk of malignancy and side effects of CST by focusing on the correlation with CST in 84 patients with type 1 AIP. RESULTS: The incidence of relapse was 23.8%. The frequency of relapse after CST administration was significantly lower in patients taking CST for >6 months than in those who did not (22% versus 67%; p = 0.036). The incidence of malignancy was 10.7%. The standardized incidence ratio of malignancy was 2.14 [95% confidence interval 0.74-3.54]. There were no significant correlations between development of malignancy and CST. The incidences of total and serious side effects due to CST were 75% and 19.1%, respectively. Relapse was the only significant independent predictive risk factor for serious side effects in a multivariate analysis (odds ratio 4.065; 95% confidence interval 1.125-14.706; p = 0.032). The cumulative dose of corticosteroid was significantly higher in patients with serious side effects than in those without (12,645 mg versus 7322 mg; p = 0.041). CONCLUSIONS: CST reduces relapse of AIP. However, CST causes serious side effects, particularly in relapsing patients. Alternative maintenance therapy to prevent relapse is needed.
24
International Consensus Diagnostic Criteria for Autoimmune Pancreatitis
Tooru Shimosegawa, Suresh T. Chari, Luca Frulloni et al. · Pancreas · 2011 · 1.5K citations
Medicine, Pathology, Autoimmunity +13
Cancer Incidence Before and After Kidney Transplantation
Claire M. Vajdic, Stephen P. McDonald, Margaret McCredie et al. · JAMA · 2006 · 1.1K citations
Medicine, Nephrology, Oncology +14
Standard steroid treatment for autoimmune pancreatitis
T Kamisawa, Tooru Shimosegawa, Kazuichi Okazaki et al. · Gut · 2009 · 722 citations
Cancer risk following organ transplantation: a nationwide cohort study in Sweden
Johanna Adami, H Gäbel, B Lindelöf et al. · British Journal of Cancer · 2003 · 691 citations · Full text
Medicine, Dermatology, Oncology +17
Long-term outcomes of autoimmune pancreatitis: a multicentre, international analysis
Phil A. Hart, Terumi Kamisawa, William R. Brugge et al. · Gut · 2012 · 582 citations · Full text